Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATNFNASDAQ:CWBRNASDAQ:DRMANASDAQ:KTTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNF180 Life Sciences$0.89$1.00$0.66▼$17.75$4.62M0.27799,160 shs81,607 shsCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/ADRMADermata Therapeutics$0.84+11.3%$1.02$0.69▼$6.17$4.54M0.581.17 million shs355,104 shsKTTAPasithea Therapeutics$1.66+1.2%$1.29$0.92▼$7.69$4.49M0.59968,942 shs44,174 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNF180 Life Sciences+0.56%+1.14%-13.59%-36.88%-54.59%CWBRCohBar0.00%0.00%0.00%0.00%-52.33%DRMADermata Therapeutics+0.80%+6.22%-35.76%-37.36%-84.31%KTTAPasithea Therapeutics-2.96%+6.49%+22.39%-33.87%-76.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNF180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/ADRMADermata Therapeutics2.9196 of 5 stars3.55.00.00.03.60.00.6KTTAPasithea Therapeutics0.5151 of 5 stars0.02.00.00.02.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNF180 Life Sciences 0.00N/AN/AN/ACWBRCohBar 0.00N/AN/AN/ADRMADermata Therapeutics 3.00Buy$6.00615.82% UpsideKTTAPasithea Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CWBR, ATNF, KTTA, and DRMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)4/8/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/22/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/7/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)2/19/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)2/1/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNF180 Life SciencesN/AN/AN/AN/A($0.24) per shareN/ACWBRCohBarN/AN/AN/AN/A$5.27 per shareN/ADRMADermata TherapeuticsN/AN/AN/AN/A$24.24 per shareN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$22.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNF180 Life Sciences-$19.93MN/A0.00∞N/AN/A-558.93%-54.10%5/21/2025 (Estimated)CWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/ADRMADermata Therapeutics-$7.80M-$16.41N/A∞N/AN/A-247.39%-179.72%5/7/2025 (Estimated)KTTAPasithea Therapeutics-$15.96M-$12.69N/A∞N/AN/A-81.57%-74.31%5/13/2025 (Estimated)Latest CWBR, ATNF, KTTA, and DRMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/24/2025Q4 2024KTTAPasithea TherapeuticsN/A-$2.41N/A-$2.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNF180 Life SciencesN/AN/AN/AN/AN/ACWBRCohBarN/AN/AN/AN/AN/ADRMADermata TherapeuticsN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNF180 Life SciencesN/A0.190.19CWBRCohBarN/AN/AN/ADRMADermata TherapeuticsN/A3.443.44KTTAPasithea TherapeuticsN/A14.8214.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNF180 Life Sciences4.07%CWBRCohBar2.47%DRMADermata Therapeutics8.67%KTTAPasithea Therapeutics23.92%Insider OwnershipCompanyInsider OwnershipATNF180 Life Sciences0.17%CWBRCohBar6.51%DRMADermata Therapeutics9.40%KTTAPasithea Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNF180 Life Sciences75.19 million3.17 millionNo DataCWBRCohBar102.91 millionN/ANot OptionableDRMADermata Therapeutics86.03 million1.85 millionNot OptionableKTTAPasithea Therapeutics32.71 million1.06 millionNot OptionableCWBR, ATNF, KTTA, and DRMA HeadlinesRecent News About These CompaniesPasithea Therapeutics Advances Clinical Trial of PAS-004 for Neurofibromatosis and MAPK Pathway Driven CancersApril 29 at 7:22 AM | quiverquant.comPasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer PatientsApril 29 at 7:02 AM | globenewswire.comPasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual MeetingApril 24, 2025 | globenewswire.comPasithea Reports Positive Safety Review Committee Recommendation From Phase 1 Study Of PAS-004April 11, 2025 | nasdaq.comPasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing CohortApril 11, 2025 | msn.comPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerApril 10, 2025 | globenewswire.comPasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer ConferenceMarch 24, 2025 | finance.yahoo.comKTTA stock touches 52-week low at $1.32 amid market challengesFebruary 12, 2025 | msn.comPasithea Therapeutics Shares Rise After Positive Safety Review for Cancer TreatmentFebruary 6, 2025 | marketwatch.comBig Mid-Week Move From This Small BiotechFebruary 6, 2025 | msn.comPasithea announces Safety Review Committee recommendationFebruary 6, 2025 | markets.businessinsider.comPasithea's PAS-004 advances in cancer trial with no toxicitiesFebruary 6, 2025 | msn.comPasithea Therapeutics Advances PAS-004 Clinical Trial to Next Dose Level Following Safety Review Committee RecommendationFebruary 5, 2025 | quiverquant.comPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerFebruary 5, 2025 | globenewswire.comKTTA stock touches 52-week low at $2.19 amid market challengesJanuary 31, 2025 | msn.comPasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4January 14, 2025 | globenewswire.comPasithea Therapeutics announces SRC recommended proceeding to cohort 4November 20, 2024 | markets.businessinsider.comPasithea Therapeutics Advances PAS-004 Clinical Trial to Next Dose Level Following Positive Safety Review FindingsNovember 20, 2024 | quiverquant.comPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNovember 20, 2024 | globenewswire.comCrude Oil Down Over 2%; US Initial Jobless Claims FallSeptember 27, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCWBR, ATNF, KTTA, and DRMA Company Descriptions180 Life Sciences NASDAQ:ATNF$0.89 0.00 (0.00%) As of 04:00 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.CohBar NASDAQ:CWBR$0.41 0.00 (0.00%) As of 01/23/2025CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Dermata Therapeutics NASDAQ:DRMA$0.84 +0.08 (+11.27%) As of 04:00 PM EasternDermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Pasithea Therapeutics NASDAQ:KTTA$1.66 +0.02 (+1.22%) As of 04:00 PM EasternPasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
